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Abstract 
 
The free-exploratory paradigm (FEP) has been proposed as a model of trait 
anxiety for both mice and rats. However, its pharmacological validation has only 
been carried out for mice. Thus, the aim of the present study was to 
pharmacologically validate FEP for Wistar rats, by testing the effects of clinically 
established anxiolytic and anxiogenic drugs, in four different experiments. In all 
experiments, male Wistar rats were first tested in FEP to be categorized 
according to their levels of trait anxiety (high, medium and low). Then, only 
medium trait anxiety rats were selected to be tested again in FEP, two weeks 
later, after being pharmacologically treated, according to each experiment as 
follows: Experiment I: 0.5 mg/kg of diazepam (DZP) or vehicle; Experiment II: 
20 mg/kg of pentylenetetrazole (PTZ) or vehicle; Experiment III: 5 mg/kg of 
fluoxetine (FLX5) or vehicle:  and Experiment IV: 0.5 mg/kg of fluoxetine 
(FLX0.5) or vehicle. As a group, the results showed that PTZ and FLX5 
increased levels of trait anxiety and reduced locomotor activity, whereas DZP 
and FLX0.5 decreased levels of trait anxiety, without impairing locomotor 
activity. These results demonstrate that FEP for rats is able to predict clinical 
anxiolytic and anxiogenic activities of different drugs, including fluoxetine, which 
is believed to present a dual effect on anxiety. Therefore, this paradigm can be 
proposed as an effective method for testing potential trait anxiety-reducing 
drugs, in rats. 
 
 
 
1. Introduction 
Anxiety disorders are associated with significant impairment in quality of 
life and negative interferences on occupational, academic and social contexts 
(Olatunji et al., 2007), being the most prevalent class of psychiatric disorders in 
the general population (Kessler et al., 2005) and the third most expensive brain 
disorder in Europe, with an economic cost of billions of euros (Olesen et al., 
2012). However, its treatment is still challenging, as the drugs used for the relief 
of anxiety symptoms can have important side-effects, promote therapeutic 
dependence, or present a delay in their onset of action (Starcevic, 2005). 
Furthermore, not all patients benefit from the available treatments, and only a 
few of them have a response near to complete recovery (Ravindran, 2010). 
These facts justify the growing number of studies in order to develop more 
effective drugs, with fewer side-effects, for the control of anxiety disorders. 
For the experimental evaluation of new drugs with a potential anxiolytic 
effect, the scientific community counts on various animal models. However, 
most of these models confront the animals with an anxiety provoking situation, 
either through anxiogenic chemicals (β-carbolines, yohimbine, caffeine), conflict 
tests (Geller and Seifter box, light/dark chamber, elevated plus-maze) or 
exposure to aversive stimuli (defensive burying; Martin, 1998; Garner et al., 
2009; Treit, 2010; McGonigle, 2014), thus modelling state anxiety, which is the 
anxiety a subject experiences at a particular moment in time, in response to a 
threatening situation. However, in the study of anxiety there is another important 
concept: trait anxiety, which describes individual differences, related to a 
tendency to present state anxiety, is relatively stable overtime (Spielberger, 
1970; Treit, 2010) and is high in anxiety disorder patients (Bieling et al., 1998; 
Kennedy et al., 2001). 
The underlying biological mechanisms of state and trait anxiety may not 
be the same (Treit et al., 2010). It has been shown that the anxiety response to 
a threatening stimulus involves brain structures such as amygdala, bed nucleus 
of the stria terminalis, septo-hippocampal system, median raphe nucleus, 
ventral periaqueductal grey matter and locus coeruleus (Gray and Mcnaughton, 
2000; Brandão et al., 2003; Davis, 2006); while the anxious trait is thought to be 
related to the orbitofrontal cortex (Kalin et al., 2007; Blackmon et al., 2011). 
Therefore, it is reasonable to believe that a drug that is effective in animal 
models of state anxiety, and which may therefore reduce state anxiety in 
humans in threatening situations, might not be effective in reducing long-term 
anxiety in chronically anxious patients.  
Taking all this into consideration, it becomes clear that pre-clinical tests 
for the development of new anxiolytic drugs should include animal models of 
trait anxiety. 
To the best of our knowledge, the only test that has been proposed as an 
animal model o trait anxiety is the free-exploratory paradigm (FEP) (Griebel 
1993, Teixeira-Silva et al., 2009; Oliveira et al., 2014). In this model, animals 
are given the opportunity to move around freely within an environment 
containing both familiar and novel parts. This approach allows the evaluation of 
neophobic responses. As the animals have a choice between novelty and 
familiarity, it is expected that individuals with low trait anxiety would exhibit a 
preference for novelty, whereas high trait anxiety subjects would prefer 
familiarity. 
FEP has been performed in both mice (Misslin et al. 1982; Misslin and 
Cigrang, 1986; Griebel et al., 1993; Belzung and Le Pape, 1994) and rats 
(Hughes, 1968; Matos et al., 2011; Goes et al., 2013), yet its pharmacological 
validation has only been carried out for mice (Belzung and Berton, 1997; 
Belzung et al., 2001). 
With this in mind, the aim of the present study was to validate 
pharmacologically FEP in Wistar rats. 
 
2. Material and methods 
2.1. Animals 
One hundred thirty-four adult (2–3 months) male Wistar rats were 
obtained from our own colony. The animals were kept five per cage (41 × 34 × 
18 cm), in a temperature (22–24 °C) and light (12 h/12 h light/dark cycle; lights 
on at 06:00 a.m.) controlled room, with water and food ad libitum.  
All procedures were approved by the local ethical committee 
(Universidade Federal de Sergipe) and complied with both national (Brazilian 
National Council on the Control of Animal Experimentation – Law 11.794, of 
October 8, 2008) and international guidelines (Council Directive 2010/63/EU of 
the European Parliament and of the Council of 22 September 2010) for the care 
of animals. 
 2.2. Free-exploratory paradigm  
The Free-exploratory paradigm was set up as described by Antunes et 
al. (2011). The apparatus (Fig. 1) consisted of a wooden box, divided into two 
compartments, with each of these further subdivided into three exploratory units 
(20 x 20 cm), interconnected by small openings.  The two compartments were 
separated by a removable partition. The box was placed on a stand in the rat 
home room. Approximately 24h before testing, the partition was installed and an 
animal was put into one half of the apparatus and left there until the test time, in 
order to become familiarized with it. This familiar half had fresh zeolites (Zoocel 
Biotério® - Celta Brasil, Cotia, BR) covering the floor and the animal had free 
access to food and water. On the test day the partition, between the familiar and 
the novel compartments was removed and the animal was observed for 15 
minutes, under infra-red light.  During this period, the following parameters were 
measured: total distance travelled (TDT), and the time spent in each 
compartment, from which the percentage of time spent in the novel side 
(%TNS) – a parameter considered a reliable measure of trait anxiety in rats 
(Teixeira-Silva et al., 2009). These parameters were measured using a 
computerized system for animal tracking (Anymaze, Stoelting Co., Wood Dale, 
Illinois, USA).  
 
2.3. Drugs 
Fluoxetine Hydrochloride (EMS – Sigma Pharma Ltda., Brazil), and 
pentylenetetrazole (Sigma-Aldrich™, USA) were dissolved in saline and 
diazepam (EMS S/A, Brazil) was dissolved in 5% alcohol solution. All drugs 
were administered intraperitonially (i.p.), in a volume of 2 ml/kg body weight.  
 
2.4. Procedure 
Four experiments, following the same procedure, were performed aiming 
to pharmacologically validate FEP, in Wistar rats. 
A total of 134 rats were first tested on the FEP (FEP1) as described 
above. The obtained results were used to classify them according to the %TNS, 
as presenting high (%TNS < 51.17), medium (51.17 < %TNS < 80.00) or low 
(%TNS > 80.00) levels of trait anxiety, in conformity with a previous 
categorization performed in our lab (Goes et al., 2013). After FEP1, only the 
animals with medium anxiety (n = 66) were selected for the study. They were 
put back into their home cages, and kept under standard conditions (described 
in the “Animals” section), until tested again in FEP (FEP2), two weeks later. In 
this second exposition, before the behavioural evaluation, the animals were 
pharmacologically treated as follows: 
- Experiment I: 0.5 mg/kg of diazepam (DZP; n = 10) or vehicle (5% 
alcohol solution + saline, CTRL; n = 10), 30 minutes before evaluation. 
- Experiment II: 20 mg/kg of pentylenetetrazole (PTZ; n=6) or vehicle 
(saline, CTRL; n=6), 15 minutes before evaluation. 
- Experiment III: 5 mg/kg of fluoxetine (FLX5; n=8) or vehicle (saline, 
CTRL; n= 8), 30 minutes before evaluation. 
- Experiment IV: 0.5 mg/kg of fluoxetine (FLX0.5; n=10) or vehicle (saline, 
CTRL; n=10), 30 minutes before evaluation. 
Between each use, the free-exploratory boxes were emptied and then 
cleaned using a 10% ethanol solution. 
All tests were performed in the dark phase of the light/dark cycle, 
between 6:00 and 7:00 p.m.  
2.5. Statistical Analysis 
The obtained data from all experiments were first analysed using 
Kolmogorov–Smirnov’s test for normal distribution and Levene’s test for the 
homogeneity of variances. No impediments to the use of parametric tests were 
found for any of the evaluated parameters. 
The data were analysed by two-way ANOVA for repeated measures 
(factor 1: treatment; factor 2: trial). When the interaction between factors was 
significant, the analyses were followed fixing factor 1 and conducting one-way 
ANOVA for repeated measures; and fixing factor 2 and conducting one-way 
ANOVA for independent samples. 
All significance tests were performed at the 5% significance level. 
In all experiments, a z-score was calculated for all parameters and 
animals presenting values outside the between mean ± two standard deviations 
were excluded from the analysis.  
 
3. Results 
3.1. Experiment I (Fig. 2) 
After the z-score calculation, the sample sizes for each group were as 
follows: CTRL (n=9) and DZP (n=9). 
There was not significant interaction between treatment and trial for the 
TDT parameter (F1, 16=1.318; p=0.267); therefore, the two main effects were 
analysed. Neither treatment [F(1,16)=3.4560; p=0.08] or trial [F(1,16)=0.657; 
p=0.429] changed TDT significantly. 
Analysis of %TNS showed significant interaction between treatment and 
trial [F(1,16)=12.916; p=0.002]. Fixing factor treatment, analysis of the trial as a 
single factor showed that DZP spent more time in the novel side on FEP2 in 
comparison to FEP1 [F(1,8)=22.528; p=0.001], while no differences were found 
for CTRL [F(1,8)=3.855; p=0.08]. Fixing factor trial, analysis of the treatment as 
a single factor showed that DZP spent more time in the novel side in relation to 
CTRL on FEP2 [F(1,16)=7.696; p=0.013], while no differences were found on 
FEP1 [F(1,16)=2.421; p=0.139]. 
 
3.4 Experiment II (Fig. 3) 
After the z-score calculation, the sample sizes for each group remained 
the same: CTRL (n=6) and PTZ (n=6). 
There was significant interaction between treatment and trial for the TDT 
parameter [F(1,10)=18.979; p=0.001]. Fixing factor treatment, analysis of the 
trial as a single factor showed that the PTZ reduced TDT on FEP2 in relation to 
FEP1 [F(1,5)=44.558; p=0.001], but no differences were found for CTRL 
[F(1,10)=0.292; p=0.612]. Fixing factor trial, analysis of the treatment as a 
single factor showed that PTZ reduced TDT in relation to CTRL on FEP2 
[F(1,10)=11.933; p=0.006], but no differences were found on FEP1 
[F(1,10)=0.076; p=0.789]. 
 Analysis of %TNS showed significant interaction between treatment and 
trial [F(1,10)=10.135; p=0.009]. Fixing factor treatment, analysis of the trial as a 
single factor showed that PTZ spent less time in the novel side on FEP2 in 
comparison to FEP1 [F(1,5)=12.889; p=0.015], while no differences were found 
for CTRL [F(1,5)=0.251; p=0.637]. Fixing factor trial, analysis of the treatment 
as a single factor showed that PTZ spent less time in the novel side in relation 
to CTRL on FEP2 [F(1,10)=13.295; p=0.004], while no differences were found 
on FEP1 [F(1,10)=0.586; p=0.462]. 
 
3.2 Experiment III (Fig. 4) 
After the z-score calculation, the sample sizes for each group remained 
the same: CTRL (n=8) and FLX5 (n=8). 
There was a significant interaction between treatment and trial for the 
TDT parameter [F(1,13)=16.607; p=0.001]. Fixing factor treatment, analysis of 
the trial as a single factor showed that FLX5 reduced TDT on FEP2 in relation 
to FEP1 [F(1,7)=27.665; p=0.001], but no differences were found for CTRL 
[F(1,6)=0.152; p=0.710]. Fixing factor trial, analysis of the treatment as a single 
factor showed that FLX5 reduced TDT in relation to CTRL on FEP2 
[F(1,14)=10.257; p=0.006], but no differences were found on FEP1 
[F(1,14)=0.271; p=0.610].  
Analysis of %TNS showed significant interaction between treatment and 
trial [F(1,13)=5.814; p=0.031]. Fixing factor treatment, analysis of the trial as a 
single factor did not reveal significant differences for either FLX5 
[F(1,13)=5.042; p=0.059] or CTRL [F(1,6)=1.340; p=0.291]. Fixing factor trial, 
analysis of the treatment as a single factor showed that FLX5spent less time in 
the novel side in relation to CTRL on FEP2 [F(1,14)=5.298; p=0.037], while no 
differences were found on FEP1 [F(1,14)=0.650; p=0.433]. 
 
3.3 Experiment IV (Fig. 5) 
After the z-score calculation, the sample sizes for each group were as 
follows: CTRL (n=9) and FLX0.5 (n=10). 
There was no significant interaction between treatment and trial for the 
TDT parameter [F(1,17)=0.0425; p=0.839]; therefore, the two main effects were 
analysed. Neither treatment [F(1,17)=1.717; p=0.207)] or trial [F(1,17)=0.0004; 
p=0.985] changed TDT significantly.  
Analysis of %TNS showed significant interaction between treatment and 
trial [F(1,17)=4.642; p=0.045]. Fixing factor treatment, analysis of the trial as a 
single factor showed that FLX0.5 spent more time in the novel side on FEP2 in 
comparison to FEP1 [F(1,179)=14.848; p=0.003], while no differences were 
found for CTRL [F(1,8)=0.480; p=0.507]. Fixing factor trial, analysis of the 
treatment as a single factor showed that FLX0.5 spent more time in the novel 
side in relation to CTRL on FEP2 [F(1,17)=6.278; p=0.022], while no differences 
were found on FEP1 [F(1,17)=0.240; p=0.630]. 
 4. Discussion 
The aim of the present study was to pharmacologically validate FEP in 
Wistar rats. In the pharmacological validation of FEP in mice (Griebel et al., 
1993), two strains were used, BALB/c and C57BL/6, known respectively as 
“emotional” and “non-emotional”. As a result, anxiolytic effects were only 
observed in BALB/c mice, since the basal levels of novel side exploration of 
C57BL/6 mice was too high. Based on this, for the present study, only animals 
presenting medium trait anxiety were selected for the pharmacological tests, 
because their anxiety levels could either go up or down.  This way, it was 
possible to observe both anxiolytic and anxiogenic effects in the same rat strain. 
Three different drugs were used: 1) diazepam, which belongs to the class 
of benzodiazepines, which are typically used for the pharmacological validation 
of animal models (Andreatini, 2001); 2) pentylenetetrazole, a convulsant 
compound GABA-benzodiazepine receptor blocker (Huang et al., 2001), which 
induces anxiety in lower doses (subconvulsant; Pellow et al., 1985); and 3) 
fluoxetine, a selective serotonin reuptake inhibitor, which has been highlighted 
as the most prescribed drug for the relief of anxiety symptoms (Marshall, 2009). 
Before initiating Experiment I, a pilot study was conducted in our 
laboratory using two doses of diazepam, 0.5 mg/kg and 2 mg/kg. According to 
the FDA (Center for Drug Evaluation and Research, 2002), these doses are 
equivalent to the ones that present anxiolytic effects in mice tested in FEP (1 
mg/kg and 4 mg/kg, respectively; Griebel et al., 1993). However, the animals 
that received 2 mg/kg of diazepam remained motionless for almost the whole 
test, preventing behavioural evaluation. Thus, 0.5 mg/kg was chosen to be 
tested. The results obtained from Experiment I showed that diazepam reduces 
trait anxiety, without impairing locomotor activity, in rats  
Pentylenetetrazole (PTZ) used in Experiment II, increased levels of trait 
anxiety, as expected, and reduced locomotor activity. This hypolocomotor effect 
of PTZ is well known (Pellow, et al., 1985; Ramos et al., 1997; Ramos et al., 
2008). 
Similar results were observed with the administration of 5 mg/kg of 
fluoxetine (Experiment III). A locomotor activity reduction by fluoxetine has been 
observed before (Silva et al., 1999; Robert et al., 2011; Birket et al 2011) as 
well as its anxiogenic effect (Drapier et al., 2007; Birket et al 2011). Despite its 
extensive clinical use for the treatment of anxiety, fluoxetine displays 
controversial results in studies with animal models. Administered either acutely 
or chronically, fluoxetine can present anxiogenic, anxiolytic or no effects (De Vry 
et al., 2004; Borelli et al., 2004; Robert et al., 2011). Some differences in 
experimental protocols can be related to these conflicting results. For example, 
Silva and Brandão (2000) observed that chronic fluoxetine added to the drinking 
water had no effect in anxiety, while Robert et al. (2011) observed that chronic 
fluoxetine administered intraperitoneally had an anxiogenic effect. This result 
was observed in Wistar rats, receiving 5 mg/kg of fluoxetine; but Griebel et al. 
(1999) could not see the same in Wistar-Kyoto rats. An anxiolytic effect of 20 
mg/kg of fluoxetine can be seen on the elevated plus-maze after 24 h, but not 
after 30 min (Griebel et al.,1999). Thus, it seems that different strains, doses, 
administrations routes and paradigms can change fluoxetine results.  
Interestingly, while conducting a pilot study in our laboratory, an 
anxiolytic effect of fluoxetine, without impairment of locomotor activity, was 
found in FEP. Later, it was realised that an error had occurred during the 
preparation of the fluoxetine solution, which ended up being 10 times less 
concentrated, so that the animals received 0.5 mg/kg, instead of 5 mg/kg, of 
fluoxetine. In order to confirm this finding, Experiment IV was performed and its 
results demonstrated that 0.5 mg/kg of fluoxetine indeed decreased levels of 
trait anxiety and did not change locomotor activity. It has been demonstrated, 
through in vivo brain microdialysis, that low doses of a serotonin reuptake 
inhibitor, acutely administered, seems to significantly increase levels of 
extracellular 5-HT in raphe nuclei (Adell  and Artigas, 1991;  Invernizzi  et al. 
1992). This increase stimulates presynaptic 5-HT1A autoreceptors, which are 
responsible for inhibiting the activity of 5-HT neurons in raphe nuclei. According 
to the 5-HT hypothesis of anxiety, this inhibition would generate an anxiolytic 
effect, as acute increases in 5-HT neurotransmission induces anxiety, while a 
decrease could induce anxiolysis (Griebel et al., 1996). 
In summary, our results showed that FEP was able to predict both anxiolytic 
and anxiogenic effects of clinically used drugs, supporting the validity and 
appropriateness of this model as a test to investigate the pharmacological 
activities of different drugs in trait anxiety.  
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Figure Legends 
Fig. 1. Free-exploratory box with a rat in the novel side (right side). The left side 
corresponds to the familiar environment.  
Fig. 2. Total distance travelled (A) and percentage of time spent in the novel 
side (B) of the Free-exploratory Paradigm (FEP). DZP: 0.5 mg/kg of diazepam; 
CTRL: vehicle. FEP1: first exposure to FEP (drug naive rats). FEP2: second 
exposure to FEP (pharmacologically treated rats). Data are presented as 
means ± SEM. *p<0.05 in relation to FEP1. #p<0.05 in relation to CTRL on 
FEP2. 
Fig. 3. Total distance travelled (A) and percentage of time spent in the novel 
side (B) of the Free-exploratory Paradigm (FEP). PTZ: 20 mg/kg of 
pentylenetetrazole; CTRL: vehicle. FEP1: first exposure to FEP (drug naive 
rats). FEP2: second exposure to FEP (pharmacologically treated rats). Data are 
presented as means ± SEM. *p<0.05 in relation to FEP1. #p<0.05 in relation to 
CTRL on FEP2. 
Fig. 4. Total distance travelled (A) and percentage of time spent in the novel 
side (B) of the Free-exploratory Paradigm (FEP). FLX5: 5 mg/kg of fluoxetine; 
CTRL: vehicle. FEP1: first exposure to FEP (drug naive rats). FEP2: second 
exposure to FEP (pharmacologically treated rats). Data are presented as 
means ± SEM. *p<0.05 in relation to FEP1. #p<0.05 in relation to CTRL on 
FEP2. 
Fig. 5. Total distance travelled (A) and percentage of time spent in the novel 
side (B) of the Free-exploratory Paradigm (FEP). FLX0.5: 0.5 mg/kg of 
fluoxetine; CTRL: vehicle. FEP1: first exposure to FEP (drug naive rats). FEP2: 
second exposure to FEP (pharmacologically treated rats). Data are presented 
as means ± SEM. *p<0.05 in relation to FEP1. #p<0.05 in relation to CTRL on 
FEP2. 
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